drugset / Trial / NCT00787605

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

NCT00787605

Phase 4 Completed 860 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) given to diabetic patients with stage 2 systolic hypertension (mean sitting systolic blood pressure (msSBP) ≥ 160 mm Hg and \< 200 mm Hg).

Timeline

Start
2008-11
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Comparator Amlodipine Other / unclassified 10 mg
Subject Hydrochlorothiazide Unknown 25 mg